Design to come?

WP_Post Object
(
    [ID] => 2512
    [post_author] => 3
    [post_date] => 2025-05-06 16:03:37
    [post_date_gmt] => 2025-05-06 21:03:37
    [post_content] => 
    [post_title] => Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-inc-and-the-swiss-group-for-clinical-cancer-research-sakk-receive-european-medicines-agency-authorization-to-initiate-phase-2-invincible-4-sakk-66-22-study-for-int230-6-in-t
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2025-05-21 16:06:14
    [post_modified_gmt] => 2025-05-21 21:06:14
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=2512
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)